FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to a new dosage regimen for administering 3-[5-amino-4-(3-cyanobenzoyl)pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof, specifically in treating acute exacerbations of an inflammatory diseases.
EFFECT: disclosed is a dosing regimen for treating acute exacerbations of inflammatory conditions.
17 cl, 2 ex, 2 tbl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| DOSING REGIMEN FOR TREATING ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2016 |
|
RU2713203C1 |
| APPLICATION OF PYRAZOLE DERIVATIVE IN TREATMENT OF ACUTE ATTACKS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2013 |
|
RU2625762C2 |
| METHOD FOR PRODUCING A POLYMORPHIC FORM OF 3-[5-AMINO-4-(3-CYANOBENZOYL)PYRAZOLE-1-YL]-N-CYCLOPROPYL-4-METHYLBENZAMIDE | 2017 |
|
RU2792728C2 |
| METHOD FOR PRODUCING POLYMORPH FORM OF 3-[5-AMINO-4-(3-CYANOBENZOYL)PYRAZOLE-1-YL]-N-CYCLOPROPYL-4-METHYLBENZAMIDE | 2017 |
|
RU2765719C2 |
| DERIVATIVES OF 5-MEMBER HETEROCYCLES AS KINASE p38 INHIBITORS | 2004 |
|
RU2381219C2 |
| NOVEL SALT AND MEDICAL APPLICATION | 2012 |
|
RU2609011C2 |
| COMPOSITION OF COMPOUNDS AND WAYS OF THEIR APPLICATION | 2015 |
|
RU2659068C1 |
| TREATMENT OF HYDRADENITIS WITH JAK INHIBITORS | 2020 |
|
RU2805595C1 |
| METHOD OF SYNTHESIS OF N-(5-CYCLOPROPYL-1-QUINOLINE-5-YL-1H-PYRAZOLE-4-CARBONYL)-GUANIDINE MONOMESYLATE SALT | 2000 |
|
RU2190605C2 |
| QUINAZOLINES AS KINASE INHIBITORS | 2014 |
|
RU2662810C2 |
